News

We are pleased to announce the acquisition of a state-of-the-art 400 MHz Bruker NMR spectrometer, enhancing our advanced analytical infrastructure. The instrument supports high-resolution 1D and 2D multinuclear NMR experiments, enabling detailed structural characterization, purity analysis, and dynamic studies to support all phases of CMC development.

We are pleased to announce the addition of Cage Blender 120L and 275L to our formulation equipment range, designed for homogeneous mixing of powders and granules. These new add-on capacities enhance process flexibility and scalability to support a wider range of formulation needs.

Exemplify is on its way to building best-in-class, cutting-edge new GMP drug product R&D facilities that will allow it to provide end-to-end services ranging from GMP and non-GMP drug product development to phase 1 and 2 clinical supplies of various oral, parenteral, and topical formulation dosage forms. Our facility will be ready by Jun 2023.

Exemplify BioPharma welcomes Dr. Jay Patel, "Vice President of Formulation Development" in our newly created Pharmaceutical Sciences department. Dr. Patel has 10+ years of experience in formulation development and DP regulatory CMC. He will be leading the mission of building the formulation development capabilities at Exemplify! We are really excited to have Jay on the leadership team!

Symeres, a leading global drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), today announces the acquisition of Exemplify BioPharma (or “Exemplify”), a US based CRO that provides integrated drug development services in Process & Analytical Chemistry and Formulation Development to pharmaceutical and biotech partners. Full Press Release

Exemplify has recently relocated to a new, state-of-the-art facility. Our new, >18,000 sq. ft. laboratory has expanded room for our growing analytical, process, and formulation departments and capabilities.